Clinical Trial Update: Non-Interventional Post Marketing Surveillance Study of Neovasculgen® in Patients With Chronic Lower Limb Ischemia [Phase 4]

View source ↗

Summary

Phase 4 non-interventional post-marketing study of Neovasculgen in patients with chronic lower limb ischemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limb-threatening Ischemia
• Peripheral Artery Disease

Drugs mentioned

• Neovasculgen (VEGF165 plasmid DNA (pl-VEGF165))

Snippet

Sponsor: Artgen Biotech | Conditions: Lower Limb Ischemia | Phase 4 | Status: COMPLETED